RxDoctor Payments Data

Katherine Enos, DO

Family Medicine · Spartanburg, SCNPI 1528451002

Payments from drug & device makers

$3,052in general payments, 2019–2025

Across 154 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$597
  • Novo Nordisk$531
  • Astellas Pharma US Inc$267
  • Dexcom, Inc.$192
  • Abbott$172
  • Johnson & Johnson$170
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,052 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$94,215
Medicare patients
177
Services billed
1,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$61,053
OzempicSemaglutide46$53,884
RybelsusSemaglutide19$41,622
FarxigaDapagliflozin Propanediol22$23,911
EliquisApixaban17$19,909
Rosuvastatin Calcium358$4,979
Atorvastatin Calcium205$1,779
Levothyroxine Sodium183$1,472
Gabapentin56$1,311
SynthroidLevothyroxine Sodium20$1,222
Metoprolol Succinate68$1,171
Albuterol Sulfate HfaAlbuterol Sulfate46$1,041
ValacyclovirValacyclovir Hcl24$972
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$873
Lisinopril174$857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$531$95,50665 claims
Lilly USA, LLCMounjaro$67$61,05354 claims
AstraZenecaFarxiga$15$23,91122 claims
PfizerEliquis$154$19,90917 claims
AbbVieSynthroid$597$1,22220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →